A top priority for many individuals who are on a weight loss journey is maintaining success over the long term
If discontinuation is necessary due to side effects or other concerns, this decision should be made in consultation with the prescribing healthcare provider
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Top Product Forecasts for 2024 [1] NO
The result is a smaller but still poorly composed body
This shows that non-injectable options are possible, but it comes with very specific instructions (like taking it on an empty stomach) to ensure absorption